Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB-ARRX Cause Drug ineffective? 12 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Drug ineffective have been filed in association with RITUXIMAB-ARRX. This represents 3.5% of all adverse event reports for RITUXIMAB-ARRX.

12
Reports of Drug ineffective with RITUXIMAB-ARRX
3.5%
of all RITUXIMAB-ARRX reports
6
Deaths
8
Hospitalizations

How Dangerous Is Drug ineffective From RITUXIMAB-ARRX?

Of the 12 reports, 6 (50.0%) resulted in death, 8 (66.7%) required hospitalization, and 6 (50.0%) were considered life-threatening.

Is Drug ineffective Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB-ARRX. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB-ARRX Cause?

Product storage error (165) Circumstance or information capable of leading to medication error (116) Off label use (56) Intercepted product administration error (51) Accidental exposure to product (17) Intercepted product preparation error (16) Fatigue (14) Infusion related reaction (14) Dyspnoea (12) Malaise (12)

What Other Drugs Cause Drug ineffective?

ADALIMUMAB (71,926) METHOTREXATE (70,142) ETANERCEPT (60,367) ADAPALENE (52,181) ABATACEPT (35,212) INFLIXIMAB (33,738) TOCILIZUMAB (32,342) RITUXIMAB (32,186) LEFLUNOMIDE (31,396) HYDROXYCHLOROQUINE (31,057)

Which RITUXIMAB-ARRX Alternatives Have Lower Drug ineffective Risk?

RITUXIMAB-ARRX vs RITUXIMAB-PVVR RITUXIMAB-ARRX vs RIVAROXABAN RITUXIMAB-ARRX vs RIVASTIGMINE RITUXIMAB-ARRX vs RIVOTRIL RITUXIMAB-ARRX vs RIZATRIPTAN

Related Pages

RITUXIMAB-ARRX Full Profile All Drug ineffective Reports All Drugs Causing Drug ineffective RITUXIMAB-ARRX Demographics